Dr. Hubert Birner
Dr. Birner is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.
He currently serves as Chairman of the board of directors for leon nanodrugs GmbH and AL-S Pharma AG. He is also a Supervisory Board member of Centogene AG and Spepharm Holdings BV. Among others, Dr. Birner previously served on the board of Acer Therapeutics, Argos Therapeutics, Horizon Pharma Inc., Bioxell SA, Evotec AG, Jerini AG, Probiodrug AG and Proteon Therapeutics Inc.
Prior to his current tenure at TVM since 2000, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, joint venture structuring and business development.
Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.